Search research articles
Contact Us
Filters
Showing results (261-270 of 513) with videos related to
Page
of 52
Sort By:
American Journal of Clinical Oncology
|
June 1, 2002
A phase III randomized trial of combined chemoradiotherapy versus radiotherapy alone in locally advanced non-small-cell lung cancer
Tae-You Kim, Sung Hyun Yang, Se Hoon Lee, et al.
Radiation Oncology (London, England)
|
December 15, 2018
Clinical outcomes of radiation therapy for clinical T4b oesophageal cancer with airway invasion
Hakyoung Kim, Dongryul Oh, Yong Chan Ahn, et al.
Translational Oncology
|
December 26, 2021
Clinical significance of circulating tumor cells after chemotherapy in unresectable pancreatic ductal adenocarcinoma
Hyemin Kim, Chan Mi Heo, Jinmyeong Oh, et al.
BMC Cancer
|
August 30, 2019
NPM1 as a potential therapeutic target for atypical teratoid/rhabdoid tumors
Ji Hoon Phi, Choong-Hyun Sun, Se-Hoon Lee, et al.
Journal of Microbiology and Biotechnology
|
September 25, 2014
Soluble expression and purification of receptor activator of nuclear factor-kappa B ligand using Escherichia coli
Sol-Ji Park, Se-Hoon Lee, Kwang-Jin Kim, et al.
Lung Cancer (Amsterdam, Netherlands)
|
July 20, 2019
Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma
Sehhoon Park, Joon Ho Shim, Boram Lee, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
July 18, 2015
Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status
Jaemoon Koh, Heounjeong Go, Bhumsuk Keam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 20, 2018
Integrin β3 Inhibition Enhances the Antitumor Activity of ALK Inhibitor in <i>ALK</i>-Rearranged NSCLC
Ka-Won Noh, Insuk Sohn, Ji-Young Song, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 25, 2002
Efficacy of modified regimen with attenuated doses of paclitaxel plus carboplatin combination chemotherapy in elderly and/or weak patients with advanced non-small cell lung cancer
In Sil Choi, Byung Su Kim, Sook Ryun Park, et al.
Oncoimmunology
|
February 21, 2020
Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment
Kyung Hwan Kim, Joon Young Hur, Jinhyun Cho, et al.
Page
of 52
Search research articles
Search
Showing results (261-270 of 513) with videos related to
Sort By:
Page
of 52
American Journal of Clinical Oncology
|
June 1, 2002
A phase III randomized trial of combined chemoradiotherapy versus radiotherapy alone in locally advanced non-small-cell lung cancer
Tae-You Kim, Sung Hyun Yang, Se Hoon Lee, et al.
Radiation Oncology (London, England)
|
December 15, 2018
Clinical outcomes of radiation therapy for clinical T4b oesophageal cancer with airway invasion
Hakyoung Kim, Dongryul Oh, Yong Chan Ahn, et al.
Translational Oncology
|
December 26, 2021
Clinical significance of circulating tumor cells after chemotherapy in unresectable pancreatic ductal adenocarcinoma
Hyemin Kim, Chan Mi Heo, Jinmyeong Oh, et al.
BMC Cancer
|
August 30, 2019
NPM1 as a potential therapeutic target for atypical teratoid/rhabdoid tumors
Ji Hoon Phi, Choong-Hyun Sun, Se-Hoon Lee, et al.
Journal of Microbiology and Biotechnology
|
September 25, 2014
Soluble expression and purification of receptor activator of nuclear factor-kappa B ligand using Escherichia coli
Sol-Ji Park, Se-Hoon Lee, Kwang-Jin Kim, et al.
Lung Cancer (Amsterdam, Netherlands)
|
July 20, 2019
Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma
Sehhoon Park, Joon Ho Shim, Boram Lee, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
July 18, 2015
Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status
Jaemoon Koh, Heounjeong Go, Bhumsuk Keam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 20, 2018
Integrin β3 Inhibition Enhances the Antitumor Activity of ALK Inhibitor in <i>ALK</i>-Rearranged NSCLC
Ka-Won Noh, Insuk Sohn, Ji-Young Song, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 25, 2002
Efficacy of modified regimen with attenuated doses of paclitaxel plus carboplatin combination chemotherapy in elderly and/or weak patients with advanced non-small cell lung cancer
In Sil Choi, Byung Su Kim, Sook Ryun Park, et al.
Oncoimmunology
|
February 21, 2020
Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment
Kyung Hwan Kim, Joon Young Hur, Jinhyun Cho, et al.
Page
of 52